- Home
- GDOT vs MYGN Comparison
GDOT vs MYGN Comparison
Compare GDOT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDOT | MYGN |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.8M | 625.5M |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GDOT | MYGN |
|---|---|---|
| Price | $12.09 | $5.92 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $11.00 | ★ $11.82 |
| AVG Volume (30 Days) | 659.3K | ★ 933.3K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,007,128,000.00 | $825,300,000.00 |
| Revenue This Year | $22.56 | $0.03 |
| Revenue Next Year | $11.63 | $5.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.16 | 0.21 |
| 52 Week Low | $6.13 | $3.76 |
| 52 Week High | $15.41 | $15.47 |
Technical Indicators
Market Signals| Indicator | GDOT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 32.96 |
| Support Level | $12.19 | $5.81 |
| Resistance Level | $12.59 | $6.20 |
| Average True Range (ATR) | 0.25 | 0.31 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 3.00 | 7.09 |
Price Performance
Historical ComparisonAbout GDOT Green Dot Corporation $0.001 par value
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.